The submission of a Type C meeting request to the FDA is a critical regulatory step for Oncolytics Biotech, indicating progress in the development of Pelareorep for breast cancer treatment. This move could positively influence investor perception and potentially the stock price, as it demonstrates the company's commitment to advancing its drug pipeline and getting closer to market approval.